An **Activated Protein C Resistance (APCR)** test is a specialized blood investigation used to evaluate a person’s risk for developing abnormal blood clots. Activated Protein C (APC) is a natural anticoagulant protein in the body that inactivates specific clotting factors to prevent excessive coagulation.
In APCR, the blood’s response to APC is diminished, leading to a higher tendency to form blood clots—a condition known as thrombophilia. Most commonly caused by the Factor V Leiden genetic mutation, this test measures how long it takes for plasma to clot after adding APC. Identifying APCR helps clinicians assess venous thromboembolism risk and tailor preventive therapies effectively.

An **Antiphospholipid Antibody (APLA) Profile Test** is a specialized group of blood tests used to diagnose Antiphospholipid Syndrome (APS), an autoimmune condition. In APS, the body mistakenly produces autoantibodies against its own proteins bound to phospholipids. This reaction significantly increases the risk of abnormal blood clotting in veins or arteries, as well as pregnancy complications like recurrent miscarriages.
The APLA panel typically measures three primary markers: lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Identifying these autoantibodies helps clinicians evaluate a patient's risk of thrombotic events, guiding appropriate preventive care and targeted anticoagulant treatments.

The **Apo B : Apo A1 ratio test** evaluates the balance between atherogenic (harmful) and anti-atherogenic (protective) proteins in the blood to assess cardiovascular disease risk.
**Apolipoprotein B (Apo B)** is present in destructive particles like LDL and VLDL that deposit cholesterol into artery walls, while **Apolipoprotein A1 (Apo A1)** is the primary component of HDL, which clears excess cholesterol.
Calculating the ratio of Apo B to Apo A1 provides a clearer indicator of heart disease and stroke risk than standard cholesterol panels alone. A higher ratio signifies an increased risk of plaque buildup and coronary artery disease.